Overview

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Status:
Completed

Trial end date:
2019-04-29

Target enrollment:

Participant gender:

Summary

This research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer. Doctors want to know if Abraxane is safe and effective in treating patients with lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) and epidermal growth factor receptor (EGFR) mutations.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborators:

Celgene Corporation
National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel